Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | BRAF D594N CD274 pos NRAS Q61R |
| Therapy | Dabrafenib + Sintilimab + Trametinib |
| Indication/Tumor Type | anaplastic thyroid carcinoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| BRAF D594N CD274 pos NRAS Q61R | anaplastic thyroid carcinoma | predicted - sensitive | Dabrafenib + Sintilimab + Trametinib | Case Reports/Case Series | Actionable | In a clinical case study, combination treatment with Tafinlar (dabrafenib), Sintilimab (IBI308), and Mekinist (trametinib) resulted in a complete pathological response after two cycles allowing surgery in a patient with PD-L1 (CD274)-positive (TPS=60%, CPS=80) metastatic anaplastic thyroid carcinoma harboring BRAF D594N and NRAS Q61R, who continued on treatment with ongoing remission at 9 months after treatment initiation (PMID: 37122752). | 37122752 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (37122752) | Case report: Complete response of an anaplastic thyroid carcinoma patient with NRAS Q61R/BRAF D594N mutations to the triplet of dabrafenib, trametinib and PD-1 antibody. | Full reference... |